EDITAS MEDICINE, INC. (EDIT) Cash and securities
- Total cash · latest quarter (USD): Value $211.65M; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $211.65M | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. $181.81M + $29.83M ≈ $211.65M |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 181.81M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 29.83M USD | Marketable Securities, Current |
| Cash and current securities | 211.65M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | $211.65M | (m) | $181.81M | $29.83M | (m) |
| 2026-03-31 | (m) | (m) | $123.65M | (m) | (m) |
| 2025-12-31 | $146.65M | (m) | $146.65M | $0.00 | (m) |
| 2025-09-30 | $165.65M | (m) | $165.65M | $0.00 | (m) |
| 2025-06-30 | $178.50M | (m) | $138.54M | $39.96M | (m) |
| 2025-03-31 | $220.96M | (m) | $138.69M | $82.27M | (m) |
| 2024-12-31 | $269.91M | (m) | $131.54M | $138.37M | (m) |
| 2024-09-30 | $265.09M | (m) | $95.83M | $169.26M | (m) |
| 2024-06-30 | $279.11M | (m) | $64.44M | $214.67M | (m) |
| 2024-03-31 | $296.17M | (m) | $69.23M | $226.94M | (m) |
| 2023-12-31 | $323.11M | (m) | $123.65M | $199.46M | (m) |
| 2023-09-30 | $349.62M | (m) | $82.54M | $267.08M | (m) |
| 2023-06-30 | $431.97M | (m) | $220.82M | $211.15M | (m) |
| 2023-03-31 | $318.44M | (m) | $129.02M | $189.42M | (m) |
| 2022-12-31 | $344.27M | (m) | $141.52M | $202.75M | (m) |
| 2022-09-30 | $419.62M | (m) | $210.70M | $208.91M | (m) |
| 2022-06-30 | $452.56M | (m) | $169.40M | $283.16M | (m) |
| 2022-03-31 | $488.36M | (m) | $210.88M | $277.48M | (m) |
| 2021-12-31 | $499.85M | (m) | $203.52M | $296.33M | (m) |
| 2021-09-30 | $557.84M | (m) | $259.88M | $297.96M | (m) |
| 2021-06-30 | $610.55M | (m) | $337.83M | $272.72M | (m) |
| 2021-03-31 | $625.33M | (m) | $354.92M | $270.42M | (m) |
| 2020-12-31 | $402.11M | (m) | $139.68M | $262.43M | (m) |
| 2020-09-30 | $495.31M | (m) | $279.58M | $215.73M | (m) |
| 2020-06-30 | $598.72M | (m) | $485.82M | $112.90M | (m) |
| 2020-03-31 | $414.99M | (m) | $232.85M | $182.14M | (m) |
| 2019-12-31 | $457.14M | (m) | $238.18M | $218.96M | (m) |
| 2019-09-30 | $332.62M | (m) | $104.77M | $227.84M | (m) |
| 2019-06-30 | $317.93M | (m) | $210.60M | $107.33M | (m) |
| 2019-03-31 | $342.06M | (m) | $157.93M | $184.13M | (m) |
| 2018-12-31 | $368.95M | (m) | $134.78M | $234.18M | (m) |
| 2018-09-30 | $337.49M | (m) | $111.70M | $225.79M | (m) |
| 2018-06-30 | $344.08M | (m) | $131.92M | $212.16M | (m) |
| 2018-03-31 | $358.82M | (m) | $217.67M | $141.15M | (m) |
| 2017-12-31 | $329.14M | (m) | $146.63M | $182.51M | (m) |
| 2017-09-30 | $295.69M | (m) | $86.54M | $209.15M | (m) |
| 2017-06-30 | $324.80M | (m) | $144.10M | $180.70M | (m) |
| 2017-03-31 | (m) | (m) | $351.55M | (m) | (m) |
| 2016-12-31 | (m) | (m) | $185.32M | (m) | (m) |
| 2016-09-30 | (m) | (m) | $199.87M | (m) | (m) |
| 2016-06-30 | (m) | (m) | $217.65M | (m) | (m) |
| 2016-03-31 | (m) | (m) | $229.20M | (m) | (m) |
| 2015-12-31 | (m) | (m) | $143.18M | (m) | (m) |
| 2015-09-30 | (m) | (m) | $155.30M | (m) | (m) |
| 2015-06-30 | (m) | (m) | $47.04M | (m) | (m) |
| 2015-03-31 | (m) | (m) | $5.17M | (m) | (m) |
| 2014-12-31 | (m) | (m) | $10.62M | (m) | (m) |
| 2013-12-31 | (m) | (m) | $2.01M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |